On the basis of the evidence that obese patients with ectopic fat storage, i.e., non-alcoholic fatty liver disease (NAFLD) or hepatic steatosis (HS), are at an increased CAD risk, and at the light of the conflicting results (6, 7, 10, 12) concerning the role of IL-15 in atherosclerosis, we aimed at evaluating in obesity-related NAFLD patients the serum concentrations of this cytokine and its association with IMT. This evidence concerns the gene IL15 and metabolic dysfunction-associated steatotic liver disease.